Canaccord Genuity Maintains a 'Buy' on Immunogen (IMGN); Breakthrough P2 Results Support High T-DM1 Potential

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/20/2026

1. TGT
2. EL
3. BILL
4. ADI
5. MRK
6. MRNA
7. LOW
8. TJX
9. DE
10. JKHY

September 26, 2011 8:45 AM EDT
Get Alerts IMGN Hot Sheet
Price: $31.25 --0%

Rating Summary:
    5 Buy, 17 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Immunogen Inc. (NASDAQ: IMGN) price target of $14.00.

Canaccord analyst, George Farmer, said, "We remain buyers of IMGN shares on our view of striking randomized Phase II data in front-line HER2+ metastatic breast cancer (MBC) supporting T-DM1 benefit and commercial potential. T-DM1 is an antibody-drug conjugate in development by Roche (OTC: RHHBY) to which IMGN is entitled royalties on WW product sales."

For more ratings news on Immunogen Inc. click here and for the rating history of Immunogen Inc. click here.

Shares of Immunogen Inc. closed at $10.26 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments